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1. Introduction
Growing evidence supports an active role for deregulated macroautophagy (autophagic stress)
in neuronal cell death and neurodegenerative diseases, as Parkinson’s disease (PD). The exact
etiology of PD is currently unknown, but it seems clear that its pathogenesis is a multifactorial
process. The detection of genetic alterations may be useful as a biomarker of early molecular
diagnosis, but it is also important to know and identify changes at the molecular level, more
frequent in cases of Parkinsonism. In this sense, the phenomenon of autophagic cell death,
described in the normal nervous system, could be the result of a pathological process, such as
those related to neurodegenerative diseases. Autophagy is an intracellular catabolic mecha‐
nism mediated by lysosomes, which is responsible for most of the degradation and recycling
of cytoplasmic components and intracellular organelles dysfunctional or damaged. For a long
time, it is unknown why the aggregation of proteins and developmental neurotoxicity are
given in a later period of life, even in familial forms of the disease, where the mutant protein
is present throughout life in the individual. It has been shown that genetic ablation of autoph‐
agy induces neurodegeneration and accumulation of ubiquitinated proteins. In addition, some
genetic mutations that cause neurodegenerative diseases directly affect proteolytic systems
responsible for the degradation of the mutant protein. In this paper, we analyze the possible
neuroprotective role that autophagy-inducing substances can have on the mechanism and
development of PD.
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2. Contents
2.1. The role of autophagy in PD – Importance of oxidative stress
PD is  a  progressive  neurodegenerative  disorder  characterized by slow movements  (bra‐
dykinesia), poverty of movements (hypokinesia), resting tremor and rigidity. PD is char‐
acterized pathologically by the loss of  dopaminergic neurons in the substantia  nigra pars
compacta  and  the  presence  of  Lewy  bodies  (LB),  which  are  intra-cytoplasmic  inclusions
containing high levels  of  alpha-synuclein protein.  Combined with the ubiquitous alpha-
synuclein aggregates in PD brains the finding of mutations and multiplications of the al‐
pha-synuclein gene in familial  forms of PD add to the importance of alpha-synuclein to
PD pathology.  Recent  observations  have  suggested  that  alpha-synuclein  can  be  directly
transmitted  from  pathological  affected  neurons  to  healthy  unaffected  neurons.  This  is
consistent with the Braak staging of PD pathology which suggests there is a progression
of LB pathology from the brainstem to the cortex consistent with the pathological propa‐
gation along specific neural pathways. The release of alpha-synuclein from cells and the
transfer of an aggregated form of alpha-synuclein to neighboring cells have been demon‐
strated  in  vitro  and  in  vivo  and  is  potentially  an  important  step  in  the  progression  of
PD pathology. While these processes are poorly understood, exosomes have been associ‐
ated with the release and transfer of  prion protein via a novel processing pathway that
involves the N-terminal modification of PrP and selection of distinct PrP glycoforms for
incorporation into these vesicles and there is  increasing evidence that alpha-synuclein is
also  released  from  cells  in  exosomes.  Lysosomal  dysfunction  increases  alpha-synuclein
release and transmission mediated by exosomes in cell models.
While the primary cause of PD in the majority of patients is not known, the number of genetic
causes and risk factors are gradually increasing and are beginning to highlight important
pathogenetic pathways. The role of mitochondrial dysfunction in PD is supported by the ability
of the mitochondrial toxins MPTP (1-methyl-4-phenylpyridinium) and rotenone to target the
dopaminergic neurons and more recently by PTEN-induced kinase 1 (PINK1) and parkin,
which are mutated in PD and have a role in regulating mitochondrial integrity. Oxidative stress
and damage are important observations in PD brains and are common observations in various
genetic and toxin models of PD. Protein turnover pathways have been implicated in PD, ini‐
tially involving the proteasomal system and more recently autophagy and the lysosomal path‐
ways. The G2019S mutation of leucine-rich repeat kinase 2 (LRRK2) is a relatively common
cause of PD, and recessive mutations of the lysosomal enzyme glucocerebrosidase-1 (GBA-1)
have recently been identified as one of the most important genetic risk factors for PD although
the disease mechanisms have not yet been elucidated.
Autophagy is a catabolic pathway for destruction and turnover of long-live proteins and or‐
ganelles in lysosomes. Autophagy contributes to degradation of damaged long-live proteins
and organelles and the normal turn-over of these components, moreover is up-regulated in
response to external stressors as starvation and oxidative stress. In mammalian cells autophagy
comprises three separate pathways: macroautophagy, microautophagy and chaperone-medi‐
ated autophagy (CMA).
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Macroautophagy involves the de novo formation of double membrane vacuoles, autophago‐
somes originated from mitochondria and/or plasma membrane. Autophagosomes fuse with
lysosomes to deliver cytoplasmic contents including misfolded or aggregated proteins and
organelles for digestion and recycling of amino acids. Macroautophagy is regulated at molec‐
ular level by proteins of the Atg family, which form dynamic complexes involved in the as‐
sembly, docking and degradation of the autophagosome. The serine/threonine kinase mTOR
(mammalian target of rapamicyn) is a key mediator of macroautophagy upregulation under
starvation, this protein regulates cell cycle progression, protein synthesis and cell growth. Ac‐
tivated mTOR promotes protein synthesis and inhibits catabolism by decreasing macroau‐
tophagy in a mechanism mediated by Atg13 phosphorylation that modulates Atg1 activity.
During starvation mTOR is inactivated resulting in hypophosphorylation of Atg13 and stim‐
ulation of Atg1-Atg13 complexes required for induction of autophagy.
Microautophagy involves lysosomal pinocytosis of cytoplasmic contents and is involved in
the turnover of long half-life cytosolic proteins. However, the underlying process is poorly
understood in mammalian cells.
It is important to note that both macro and microautophagy are highly conserved process that
occurs in same manner in all cells. In this sense most of the knowledge of autophagy was first
described in yeast.
CMA  is  a  selective  autophagic  pathway  dependent  upon  the  protein  chaperone  hsc70
and its  binding to LAMP-2A (Lysosomal-associated membrane protein 2A),  a  lysosomal
surface  receptor.  A highly specific  subset  of  cytosolic  proteins  with a  KFREQ motif  are
recognized by the hsc70 chaperone and internalized for degradation by Lysosomal-associ‐
ated membrane protein 2A LAMP-2A lysosomal membrane receptors. The substrate pro‐
tein is  unfolded by the complex and is  translocated to the lysosome with the help of  a
lysosomal chaperone (lys-hsc70).
Recent reports identified a increase in autophagic vacuoles, decrease in macroautophagy and
CMA proteins in PD brain areas affected by the neurodegenerative process, which might have
a direct impact in alpha-synuclein levels as this protein in degraded in lysosomes mainly by
CMA. The increase cytosolic alpha-synuclein levels favours the modification of alpha-synu‐
clein and formation of oligomers, fibrils and aggregates. Indeed, CMA is important in the
removal of oxidized and altered proteins during conditions of mild oxidative stress, and
blockage of CMA resulted in increased intracellular levels of oxidized and aggregate proteins.
Conversely the pathological environment in PD may lead to alpha-synuclein post-translational
modifications (e.g. nitration, oxidation, dopamine adducts), or oligomeric or fibrilar forma‐
tions which may not be degraded by CMA and may even inhibit CMA promoting aggregation.
Moreover, mutations in PINK1 and parkin proteins, associated with PD, affect the remove of
damaged mitochondria by lysosomes (mitophagy). Finally, other genetic mutations associated
with PD, as ATP13A2 and LRRK2, affect autophagy and lysosomal function, reinforcing the
involvement of autophagic function in PD.
Several studies described an increase in markers related with oxidative stress as protein ni‐
tration and lipid peroxidation in LB. Additional findings described a decrease in several de‐
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fense antioxidant molecules in PD including the thiol-reducing agent glutathione (GSH) and
the glutathione peroxidase activity. This increase in reactive oxygen species (ROS) levels in‐
volves an increased oxidized alteration of proteins as alpha-synuclein resulting in increasing
protein misfolding and impaired degradation, which might cause the accumulation of toxic
soluble oligomers or insoluble aggregates.
Mitochondria are the main source of ROS involved in oxidative stress and its role in PD is
highlighted by the toxic animal models (MPTP, 6-hydroxydopamine (6-OHDA), rotenone) and
the mutation in PINK1, parkin and DJ-1, involved in mitochondrial function and turnover, is
related with early onset PD. When oxidative processes clearly contribute to the pathology and
progression of PD the initiation of this cascade is probably secondary to other causes.
2.2. Toxic stress inducers related to PD
MPTP. In the early 1980s, a group of young drug abusers from Northern California developed
a parkinsonian syndrome clinically indistinguishable from PD caused by the intravenous in‐
jection of a synthetic analog of demerol. Chemical analysis of this synthetic drug showed that
it contained around 3% of MPTP. Post-mortem investigations clearly confirm the lesion of the
substantia nigra MPTP was thus considered as a powerful drug to induce nigral degeneration
both rodent and primate models of PD. Since that time, a number of environmental toxicants
have been associated with PD etiology including metals, solvents, and pesticides. Epidemio‐
logic and toxicological studies suggest a consistent correlation between pesticide exposure and
PD. MPTP is a lipophilic toxin that rapidly crosses the blood-brain barrier. Inside the brain,
MPTP is oxidized to an unstable intermediary 1-methyl-4-phenyl-2,3-dihydroxipyridinium
(MPDP+) via the action of monoamine oxidase B (MAO-B). MPDP then undergoes spontaneous
oxidation to the active toxic 1-methyl-4-phenylpiridinium (MPP+). Following its release into
the extracellular space, MPP+ is taken up by the dopamine transporter (DAT), the amino acid
transporter cationic or glutamate transporter. Once inside the cell, cytoplasmatic MPP+ can
trigger the production of ROS, which may contribute to its overall neurotoxicity. However,
the majority of MPP+ is transported into the mitochondria of dopaminergic neurons, where it
disrupts oxidative phosphorylation by inhibiting complex I activity. The inhibition of mito‐
chondrial electron transport chain causes an acute ATP deficiency, loss of mitochondrial mem‐
brane potential, alterations of intracellular calcium levels and increase ROS production,
particularly superoxide. Finally, MPP+ induces the activation of cell death signaling pathways
such as c-jun N-terminal kinase (JNK), p38 mitogen activated kinase and Bax Moreover MPTP
interact with familial PD gene products. It has reported that MPTP triggers an upregulation
of alpha-synuclein and is accompanied by PD-like modifications of alpha-synuclein, including
its aggregation, nitration and phosphorylation and modifies parkin solubility causing Parkin
aggregation.
Rotenone. Rotenone is an non mutagenic active agent of many pesticides and a well-character‐
ized, high affinity specific inhibitor of complex I of the mitochondrial respiratory chain which
emerged in the 90’s as a potential parkinsonian environmental toxin. Because it is highly lip‐
ophilic, it crosses biological membranes easily and apparently independent of specific trans‐
port system (unlike MPP+), and it gets into the brain very quickly, where accumulates within
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mitochondria and inhibits complex I. Despite this complex I inhibition, rotenone caused se‐
lective degeneration of the nigrostriatal dopaminergic pathway, selective striatal oxidative
damage, and formation of ubiquitin- and alpha-synuclein positive inclusions in nigral cells,
which were similar to the LB of PD. Furthermore, rotenone activates both mitochondrial and
endoplasmic dependent caspases that induces apoptosis. Additionally, increased oxidative
stress, ubiquitin accumulation, proteasomal inhibition and inflammation, all have been ob‐
served in response to rotenone exposure. Rotenone has also been reported to induce caspase
independent cell death, accumulation of alpha-synuclein, parkin aggregation and oxidation
mitochondrial of thioredoxin. Rotenone and MPTP share the same principle mechanism of
action and their toxic effects are quite similar. The toxicity of both compounds is linked with
glial cell activation. Microglial activation is exhibited in the rotenone rat model of Parkinson‐
ism, occurring prior to evidence of dopaminergic cell loss.
6-OHDA. 6-OHDA was the first chemical compound discovered with specific neurotoxic ef‐
fects on catecholaminergic pathways. 6-OHDA is one of the most common neurotoxins used
to experimentally model nigral degeneration in vitro as well as in vivo. 6-OHDA is a hydrox‐
ylate analogue of the natural dopamine that induces degeneration of dopaminergic neurons
in the nigrostriatal tract and is commonly used to model dopaminergic degeneration both in
vitro and in vivo. 6-OHDA is taken up into dopaminergic neurons via the dopamine transporter
although it shows high affinity for the noradrenaline transporter. Consequently, 6-OHDA can
produce specific degeneration of catecholaminergic neurons. Interestingly, 6-OHDA can be
formed from dopamine by non-enzymatic hydroxylation in presence of Fe2+ and H2O2. The
mechanism of action of 6-OHDA is related to its pro-oxidant properties. Once in the neuron,
6-OHDA accumulates in the cytosol and readily oxidizes to form ROS, mostly hydrogen per‐
oxide and paraquinone to reduce striatal levels of antioxidant enzymes and to elevate levels
of iron in the system nervous. As an additional mechanism, 6-OHDA can accumulate in the
mitochondria where interacts directly with complexes I and IV of the mitochondrial respira‐
tory chain causing respiratory inhibition and oxidative stress. Moreover, oxidized proteins by
6-OHDA induce ER stress and upregulation of the unfolded protein response (UPR), which
regulates protein translation, protein folding and protein degradation. Like dopamine and
other related compounds, 6-OHDA can be metabolized by monoamine oxidase to generate
ROS. However, pretreatment with MAO inhibitors enhances the toxicity of 6-OHDA, offering
evidence against the contributions of MAO-dependent ROS sources in the neurotoxic process.
The 6-OHDA model has been extensively used ever since and is still the most widely used tool
for replicating a PD-like loss of dopaminergic neurons in the substantia nigra pars compacta.
Paraquat. The potent herbicide paraquat (PQ, N,N’-dimethyl-1,4,4’-bipiridinium) was first
identified as a prototypic non mutagenic neurotoxin due to shares structural similarities to
MPP+, the active metabolite of MPTP. PQ is highly effective, fast-acting and non-selective her‐
bicide widely used herbicide in the world. PQ has been banned or restricted by Environmental
Protection Agency (EPA) in some countries (United States and European Union) but it still
widely used in developing countries. Because of its use as a pesticide, the possibility that this
herbicide could be an environmental contributor to the etiology of PD has received a great deal
attention. Furthermore, epidemiological studies have suggested an increased incidence of PD
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associated with PQ exposure, raising the possibility that PQ could be an environmental par‐
kinsonian toxin. It has been reported several cases of lethal poisoning resulting from ingestion
or skin contact and this is the main route of exposure of workers from prolonged contact.
Experimental studies using PQ showed that acute exposure to this pesticide had deleterious
effects on lung, liver and kidney, whereas chronic PQ exposure induced Parkinsonism. How‐
ever, significant damage to the brain is reported in individuals who died from PQ intoxication
despite the fact that the ability of PQ to cross the blood-brain barrier spontaneously is limited.
Being a charged molecule, PQ enters the brain via the neutral amino acid transporter before
Na+-dependent uptake into cells occurs. Based of its structural similarities to MPP+, the mech‐
anism of action of PQ was initially thought to be through selective complex I inhibition. How‐
ever, complex I blockade does not appear to play a significant role in PQ induced neurotoxicity
because this toxin has low affinity to mitochondrial complex I and only at high doses. Inter‐
estingly, complex III of mitochondrial respiratory chain is involved in the formation of PQ-
induced ROS in the brain. At the cytosolic levels, PQ causes cellular toxicity via redox cycling.
PQ dication (PQ2+) accepts an electron from a reductant to form PQ monocation (PQ+), which
then rapidly reacts with O2. to produce the superoxide radical (O2-) and regenerate PQ2+. The
formation of O2- initiates a series of chain reactions that lead to the generation of ROS. More‐
over, PQ produces depletion of reducing equivalents (NADPH and GSH), due to increased
oxidation, resulting in the disruption of important biochemical processes. Therefore oxidative
stress arises if antioxidant mechanisms to detoxify ROS generated are compromised resulting
in DNA, protein and lipid oxidation, ROS is involved in the mechanism by which PQ induces
dopaminergic cell death through the activation of proapoptotic signaling pathways. PQ can
trigger the sequential activation of JNK, c-Jun and caspase 3 both in vitro and in vivo, induces
cytochrome c release and caspase 9 activation, which are preceded by activation of pro-apop‐
totic Bax and Bak. PQ neurotoxicity has also been reported to require ER stress associated with
the activation of the inositol-requiring enzyme 1 (IRE1), apoptosis signal regulating kinase 1
(ASK1) and JNK. Moreover, repeated exposures of mice to the herbicide PQ increase in brain
levels of alpha-synuclein and decrease the endogenous levels of DJ-1 in vitro experiments.
2.3. Enhancers of autophagy as neuroprotectors in PD
Autophagy is involved in stress-induced adaptation as well as cellular development, dif‐
ferentiation and survival.  Regulation of  autophagy determines the fate of  cells  in multi‐
ple organs. One of the main concerns of autophagic regulation is the significance of cell-
type or tissue specificity. Specifically, neurons could be vulnerable to an accumulation of
abnormal components such as cytosolic proteins or organelles that are damaged regard‐
ing  their  post-mitotic  nature.  Therefore,  the  regulation  of  neuronal  autophagy  in  a
healthy  or  diseased environment  is  most  likely  context-dependent.  Neurons  differ  from
other  cell  types in that  they are  post-mitotic  and highly dependent  on the endo-lysoso‐
mal pathway for active signaling in the axons and dendrites. Due to these features, neu‐
rons require effective protein degradation as a quality control for cell survival, especially
under disease conditions for the removal of toxic components.  Any alteration of protein
degradation can cause the accumulation of abnormal proteins, leading to cellular toxicity
and ultimately neurodegeneration.  In this  sense,  increasing evidences suggest  that  auto‐
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phagic  deregulation  causes  accumulation  of  abnormal  proteins  or  damaged  organelles,
which is  a  characteristic  of  chronic  neurodegenerative  conditions,  such as  PD.  A viable
therapeutic strategy might be to reduce the accumulation of the toxic protein in the cyto‐
plasm. Indeed, promoting the clearance of aggregate-prone proteins via pharmacological
induction of autophagy has proved to be a useful mechanism for protecting cells against
the  toxic  effects  of  these  proteins.  An  additional  benefit  of  autophagy  upregulation  in
models of neurodegenerative diseases is that it seems to protect cells against apoptotic in‐
sults.  Some  evidence  also  indicates  that  autophagy  might  protect  cells  against  necrotic
cell death, although this mechanism has not been studied in the context of neurodegener‐
ation. Therapeutic approaches that promote autophagy could, therefore, have two benefi‐
cial  effects  in  the  context  of  neurodegenerative  diseases;  first,  they  might  improve  the
removal of toxic aggregate-prone proteins from neurons, and second, they could protect
neurons from apoptosis.
Autophagy enhancers can be classified in two groups, mTOR dependent and mTOR inde‐
pendent. For this review we will focus in the second.
Which have effect over mTOR dependent autophagy.  The very first known drug iden‐
tified as  an autophagy inducer  by mTOR pathway is  rapamycin,  which was already in
clinical use for other indications. Rapamycin is a lipophilic macrolide antibiotic original‐
ly  used  as  an  immunosuppressant.  In  mammalian  cells,  rapamycin  inhibits  the  kinase
activity  of  mTOR by forming a  complex  with  the  immunophilin  FK506-binding protein
of 12 kDa (FKBP12). Rapamycin acts specifically on the mTORC1 complex that suppress‐
es autophagy when active.
Which have effect over mTOR independent autophagy. A growing number of little molecules
has been show as autophagy inductors by a non canonical (mTOR dependent) pathway. Most
of these substances are molecules used for other pharmacological purposes and indications
including neurological diseases. We can highlight resveratrol, lithium, trehalose and carbaze‐
pine (CBZ).
Resveratrol. Resveratrol (3,5,4-trihydroxystilbene), a type of natural phenol and a phytoalexin,
is produced naturally by grapes, mulber-ries, and certain nuts when under attack by patho‐
gens. This powerful anti-oxidant possesses a broad range of bio-logical effects such as neuro‐
protection, anti-inflammation, and anti-cancer. It especially attenuates neurodegeneration in
animal models of Alzheimer’s disease and PD associated with the neuronal accumulation of
β-amyloid and alpha-synuclein, respectively. These therapeutic benefits of resveratrol in neu‐
ronal disorders are associated with activation of autophagy. A recent study showed that re‐
sveratrol protects against rotenone-mediated neurotoxicity in cellular models of PD by
autophagy induction. Recently has been described that suppression of AMPK and/or SIRT1
caused decrease of protein level of LC3-II, indicating that AMPK and/or SIRT1 are required in
resveratrol mediated autophagy induction. Moreover, suppression of AMPK caused inhibition
of SIRT1 activity and attenuated protective effects of resveratrol on rotenone-induced apop‐
tosis, suggesting that AMPK-SIRT1-autophagy pathway plays an important role in the neu‐
roprotection by resveratrol on PD cellular models.
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Lithium. For more than 60 years, lithium has been the standard pharmacological treatment for
bipolar disorder (BD), a chronic mental illness characterized by cycling between moods of
mania and depression. However, in the last two decades the role of lithium as an effective
neuroprotector has emerged. Thus, Lithium treatment inhibits the activation of caspase-3 in a
PI3K-dependent manner and prevents 6-OHDA and MPP+-induced neuronal death. Lithium's
ability to deplete free inositol and subsequently decrease IP3 levels was recently identified as
a novel route (independent of mTOR) for inducing autophagy. In this sense, in animal models,
therapeutic concentrations of lithium have been shown to facilitate clearance of the mutant
form of alpha-synuclein, an autophagy substrate. These protective effects suggest that lithium
may have substantial therapeutic potential in the treatment of PD.
Trehalose. Trehalose is a nonreducing disaccharide found in organisms from bacteria to plants,
including yeast, fungi, and invertebrates. It protects the integrity of cells against various
stresses like heat, dehydration, cold, desiccation, and oxidation by preventing protein dena‐
turation, and it is the sugar in the hemolymph of invertebrates. The majority of the protecting
properties of trehalose were discovered in yeast ; however, it also has beneficial effects in
mammals where it is not endogenously synthesized. In this sense has been recently identified
trehalose as a mTOR-independent autophagy enhancer. Although the exact mechanism by
which this drug promotes autophagy is unknown, trehalose at a relatively low concentration
disaggregates existent A53T-alpha-synuclein protofibrils and fibrils into random coil or soluble
β-sheet conformers, and trehalose at a higher concentration inhibits the formation of A53T
alpha-synuclein fibrils. In addition, by stabilizing the partially unfolded protein or activating
autophagy in an mTOR independent manner, trehalose accelerates the clearance of the aggre‐
gate-prone proteins in various neurodegenerative disorders including polyglutamine in the
R6/2 mouse model of Huntington disease, beta-amyloid in Alzheimer’s disease, and alpha-
synuclein in PD. Finally, trehalose also protected cells against several proapoptotic insults.
Carbamazepine. Carbamazepine (CBZ) is an anticonvulsant and mood-stabilizing drug used
primarily in the treatment of epilepsy and bipolar disorder, as well as certain neuralgias. The
mechanism of action of CBZ and its derivatives is relatively well understood, voltage-gated
sodium channels or potentiation of gamma-aminobutyric acid receptors are implicated. How‐
ever new effects for CBZ has been described in the last years. Thus, CBZ has been implicated
with autophagy induction through inhibition of inositol synthesis, which decreases intracel‐
lular levels of IP3. Consistent with a role for inositol depletion in autophagy regulation, CBZ
significantly reduced EGFP-HDQ74 aggregates and attenuated polyglutamine toxicity in
COS-7 cells and enhanced clearance of A30P alpha-synuclein. CBZ also significantly amelio‐
rated rotenone-induced damage in SH-SY5Y cells, by inhibiting the ROS production and in‐
hibiting neuronal apoptosis, and especially for the clearance of malfunction organelles by
autophagy induction.
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3. Conclusions and future perspectives
Future studies may focus on identifying specific molecules that modulate each step in the
autophagy pathway. Small molecules and pharmacologic agents that can more selectively
modulate certain aspects of autophagic stress may also help usher in the first wave of disease-
specific therapies. Ideally, small molecule regulators would affect only certain aspects or tar‐
gets of the autophagy pathway, since global inhibition or enhancement of protein turnover
could be problematic. In situations with substantial aggregation, however, a global induction
of autophagy may be required provided this does not outstrip the degradative capacity of the
aged or diseased cell. Promoting expression of biomolecules required for both induction and
clearance of autophagosomes may serve to prevent potential autophagic stress. To determine
the mechanism of the possible neuroprotective role of autophagy in PD would provide, even‐
tually, the design of therapeutic interventions (drugs or cell therapy) for treatment of patients
affected by this disease.
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